156 related articles for article (PubMed ID: 37585496)
21. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.
Biddlestone-Thorpe L; Sajjad M; Rosenberg E; Beckta JM; Valerie NC; Tokarz M; Adams BR; Wagner AF; Khalil A; Gilfor D; Golding SE; Deb S; Temesi DG; Lau A; O'Connor MJ; Choe KS; Parada LF; Lim SK; Mukhopadhyay ND; Valerie K
Clin Cancer Res; 2013 Jun; 19(12):3189-200. PubMed ID: 23620409
[TBL] [Abstract][Full Text] [Related]
22. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
[TBL] [Abstract][Full Text] [Related]
23. Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts.
Scheper J; Hildebrand LS; Faulhaber EM; Deloch L; Gaipl US; Symank J; Fietkau R; Distel LV; Hecht M; Jost T
Strahlenther Onkol; 2023 Dec; 199(12):1128-1139. PubMed ID: 36229655
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of triple‑negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt.
Cao W; Shen R; Richard S; Liu Y; Jalalirad M; Cleary MP; D'Assoro AB; Gradilone SA; Yang DQ
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958116
[TBL] [Abstract][Full Text] [Related]
25. Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair.
Alonso-Marañón J; Villanueva A; Piulats JM; Martínez-Iniesta M; Solé L; Martín-Liberal J; Segura S; Pujol RM; Iglesias M; Bigas A; Gallardo F; Espinosa L
Oncogene; 2021 Aug; 40(31):5042-5048. PubMed ID: 34140639
[TBL] [Abstract][Full Text] [Related]
26. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
[TBL] [Abstract][Full Text] [Related]
28. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
29. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
30. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
31. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract][Full Text] [Related]
33. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
34. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
35. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
[TBL] [Abstract][Full Text] [Related]
36. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.
Chen Y; Jiang T; Zhang H; Gou X; Han C; Wang J; Chen AT; Ma J; Liu J; Chen Z; Jing X; Lei H; Wang Z; Bao Y; Baqri M; Zhu Y; Bindra RS; Hansen JE; Dou J; Huang C; Zhou J
Nat Cell Biol; 2020 Oct; 22(10):1276-1285. PubMed ID: 33005030
[TBL] [Abstract][Full Text] [Related]
37. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract][Full Text] [Related]
38. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
39. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.
Xu R; Huang Y; Mai J; Zhang G; Guo X; Xia X; Koay EJ; Qin G; Erm DR; Li Q; Liu X; Ferrari M; Shen H
Small; 2013 May; 9(9-10):1799-808. PubMed ID: 23293085
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]